Improvement in the performance of HIV screening kits

Transfusion Medicine

Volumn 18, Issue 4, 2008, Pages 228-240

  Perry, K R ^a   Ramskill, S ^b   Eglin, R P ^b   Barbara, J A J ^b   Parry, J V ^c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c Centre for Infections Health Protection Agency

Author keywords

Automated systems; Blood screening; EIAS; HIV combination assays; HIV seroconversion; Kit evaluation; Primary HIV infection; Sensitivity; Specificity

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ARTICLE; BLOOD DONOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEXUALLY TRANSMITTED DISEASE;

BLOOD DONORS; HIV INFECTIONS; HUMANS; MASS SCREENING; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 49749083414     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2008.00874.x     Document Type: Article

References (24)

1. Barbara, J., Ramskill, S., Perry, K., Parry, J. Nightingale, M. (2007) The National Blood Service (England) approach to evaluation of kits for detecting infectious agents. Transfusion Medicine Reviews, 21, 147 158.
2. Burgess, C., Perry, K., Parry, J. Mortimer, P. (1999) Clonesystems HIV-1 and HIV-2 EIA. Medical Devices Agency Evaluation Report 99/01 (HMSO ISBN 1 85839 988 2).
3. Christiansen, C.B., Jessen, T.E., Nielsen, C. Staun-Olsen, P. (1996) False negative anti-HIV-1/HIV-2 ELISAs in acute HIV 2 infection. Vox Sanguinis, 70, 144 147.
4. Delieu, E., Donovan, L.G., Perry, K.R. Parry, J.V. (2001) Murex HIV Ag/Ab combination. Medical Devices Agency Evaluation Report 01123 (HMSO ISBN 1 84182 424 0).
5. European Parliament (1998) Directive 98/79/EC of the European Parliament and of the Council on in vitro diagnostic medical devices. Official Journal of the European Communities L331, 1 37.
6. European Parliament (2002) Commission decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices. Official Journal of the European Communities L131, 17 30.
7. Fisher, M., Pao, D., Murphy, G., Dean, G., McElborough, D., Homer, G. Parry, J.V. (2007) Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men - 10 years application. AIDS, 21, 2309 2314.
8. Gaines, H., von Sydow, M., Parry, J.V., Forsgren, M., Olav Pehrson, P., Sönnerberg, A., Mortimer, P.P. Strannegård, Ö 1998) Detection of immunoglobulin M antibody in primary human immunodeficiency virus infection. AIDS, 2, 11 15.
9. Giles, R.E., Burgess, C., Perry, K.R. Parry, J.V. (1999) Vironostika HIV Uniform II Ag/Ab. Medical Devices Agency Evaluation Report 99/51 (HMSO ISBN 1 84182 082 2).
10. Health Protection Agency (2006a) HIV and AIDS in the United Kingdom: HIV2 and HIV-1/HIV-2 co-infections. Communicable Disease Report Weekly, Vol. 16 no 17 page 10: HIV/STIs.
11. Health Protection Agency (2006b The UK Collaborative Group for HIV and STI Surveillance. A Complex Picture. HIV and other Sexually Transmitted Infections in the United Kingdom. HPA Centre for Infections, London.
12. Health Protection Agency (2007) National Guidance Note QSOP23: Commercial and in-house diagnostic assays: Evaluations and Validations. Evaluations & Standards Laboratory. HPA Centre for Infections, Evaluations and Standards Laboratory, London. www.hpa-standardmethods.org.uk
13. Kenny, C., Perry, K., Palmer, D.R. Parry, J. (1997) Murex HIV1 + 2 EIA. Medical Devices Agency Evaluation Report 97/77 (HMSO ISBN 1 85839 818 5).
14. Kenny, K., Perry, K. Parry, J. (1999) Recombigen HIV-1/HIV-2 EIA. Medical Devices Agency Evaluation Report 99/17 (HMSO ISBN 1 84182 018 0).
15. National Blood Service Surveillance Programme (2005) NBS/Health Protection Agency Surveillance Programme Annual Report WWW document URL http://www.hpa.org.uk/infections/topics_az/BIBD/publications.htm (December 2006).
16. National Blood Service Infection Surveillance (2007) NBS/Health Protection Agency Monthly Donation Testing Report, January 2007.
17. Parry, J.V., Mortimer, P.P., Perry, K.R., Pillay, D. Zuckerman, M. (2003) Towards error free HIV diagnosis: guidelines on laboratory practice. Communicable Disease & Public Health, 2003, 334 350.
18. Perry, K., Burgess, C., Harbour, S., Parry, J. Mortimer, P. (1998 Bioelisa HIV-1 + 2 EIA. Medical Devices Agency Evaluation Report 98/45 (HMSO ISBN 1 85839 920 3).
19. Perry, K.R., Kenny, C., Parry, J.V. Mortimer, P.P. (1999 bioMerieux VIDAS HIV DUO. Medical Devices Agency Evaluation Report 99/69 (HMSO ISBN 1 84182 124 1).
20. Simon, F., Ly, T.D., Baillou-Beaufils, A. et al 1994) Sensitivity of screening kits for anti-HIV 1 subtype O antibodies. AIDS, 8, 1628 1629.
21. Soldan, K., Davison, K. Dow, B. (2005) Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Eurosurveillance, 10 (1-3 17 19.
22. Tatt, I.D., Barlow, K.L., Nicoll, A. Clewley, J.P. (2001) The public health significance of HIV-1 subtypes. AIDS, 2001, S59 S71.
23. Van Binsbergen, J., Keur, W., Siebelink, A. et al 1998) Strongly enhanced sensitivity of a direct anti-HIV-1/-2 assay in seroconversion by incorporation of HIV p24 ag detection - a new generation Vironostika HIV Uni-Form II. Journal of Virological Methods, 76, 59 71.
24. Weber, B., Fall, E.-H., Berger, A. Doerr, H. (1998) Reduction of diagnostic window by new fourth generation human immunodeficiency virus screening assays. Journal of Clinical Microbiology, 36, 2235 2239.